Back to top
more

Syndax Pharmaceuticals (SNDX)

(Delayed Data from NSDQ)

$20.57 USD

20.57
589,013

-0.22 (-1.06%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $20.63 +0.06 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SNDX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Syndax Pharmaceuticals, Inc. [SNDX]

Reports for Purchase

Showing records 1 - 20 ( 43 total )

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/28/2024

Company Report

Pages: 8

4Q23 Results; Two Potential New Drug Launches in 2024; Reiterate Buy and $41 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/12/2024

Industry Report

Pages: 25

Menin Inhibitors Carving Out a Niche in Leukemias: Rationale, Opportunities, and Candidates

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 75.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/02/2024

Daily Note

Pages: 3

NDA Submitted for Revumenib in R/R KMT2Ar Acute Leukemia and BLA Submitted for Axatilimab in cGVHD

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

12/22/2023

Company Report

Pages: 8

Model Update Following Raise; Lowering Price Target by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

12/13/2023

Company Report

Pages: 8

Additional Data From the Pivotal AUGMENT-101 Trial at ASH 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/12/2023

Company Report

Pages: 9

Encouraging Data Updates For Axatilimab and Revumenib at ASH 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for SNDX 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/03/2023

Company Report

Pages: 8

3Q23 Results; Multiple Presentations Planned For ASH 2023 Annual Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/24/2023

Daily Note

Pages: 3

Revumenib NDA Submission Planned Under FDA''s Real-Time Oncology Review Program

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/02/2023

Company Report

Pages: 8

Positive Data From Pivotal AUGMENT-101 Trial of Revumenib in r/r KMT2Ar Acute Leukemia

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/04/2023

Company Report

Pages: 8

2Q23 Results; Two Potential Regulatory Filings Expected by Year-End; AUGMENT-101 Data Expected 3Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

07/24/2023

Company Report

Pages: 8

Primary Endpoint Reached Across All Dose Levels in Pivotal AGAVE-201 Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/09/2023

Company Report

Pages: 8

1Q23 Results; Top-Line Data From AUGMENT-101 Trial in KMT2Ar Acute Leukemia Patients Expected in 3Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/01/2023

Company Report

Pages: 8

4Q22 Results; Initial Top-Line Data From Pivotal AUGMENT-101 Study Expected in 3Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

12/12/2022

Company Report

Pages: 9

Updated AUGMENT-101 Phase 1 Data at ASH; Raise PT by $2

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

12/05/2022

Daily Note

Pages: 4

Revumenib Receives FDA Breakthrough Therapy Designation; Axatilimab Data Published

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

11/04/2022

Company Report

Pages: 8

3Q22 Results; Updated AUGMENT-101 Data in ASH Abstracts

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/09/2022

Company Report

Pages: 8

2Q22 Results; Data From Pivotal Studies of Revumenib and Axatilimab Expected in 1H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/10/2022

Company Report

Pages: 6

1Q22 Results; One or More AUGMENT-101 Pivotal Cohorts to Complete Enrollment in 2022; AGAVE-201 Trial Data Expected 1H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

04/11/2022

Company Report

Pages: 29

Two Potential NDA Filings in 2023; Initiating Coverage With a Buy Rating and $31 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 35.00

Research Provided by a Third Party